Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03891615 |
|
Recruitment Status :
Recruiting
First Posted : March 27, 2019
Last Update Posted : December 16, 2020
|
Sponsor:
Massachusetts General Hospital
Collaborator:
Tesaro, Inc.
Information provided by (Responsible Party):
Zofia Piotrowska, Massachusetts General Hospital
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | April 30, 2022 |
| Estimated Study Completion Date : | April 30, 2024 |